Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes B7-H3. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.

Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Abstract: Binding molecules are provided. The binding molecules specifically bind to CD16a (Fc?RIIIA) expressed on the surface of natural killer (NK) cells, but do not bind to CD16b (Fc?RIIIB). The use of such binding molecules in the stimulation and activation of primary human NK cells is also disclosed.

Abstract: The present application provides an antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2)(“multivalent anti-Ang2 antibody or antigen-binding fragment thereof”), and ii) a vascular endothelial growth factor receptor (VEGFR) component, wherein the multivalent anti-Ang2 antibody or antigen-binding fragment thereof does not inhibit the binding between Ang2 and TEK receptor tyrosine kinase (TIE2). Also provided are methods of making and uses thereof.

Abstract: Provided is a dual recombinant viral vector system for expressing, in a cell, a polypeptide molecule which is composed of two different peptide chains and has an antigen binding activity, wherein the first chain is expressed using a first viral vector, the second chain is expressed using a second viral vector, and the first and second chains can be assembled, after being expressed in a cell, into the polypeptide molecule which has an antigen binding activity. Further provided are a dual plasmid system for the production of the dual recombinant viral vector system, a host cell containing the dual recombinant viral vector system, a pharmaceutical composition, and the use of and the method for delivering the polypeptide molecule to a subject by using the dual recombinant viral vector system.

Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Abstract: The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Abstract: The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.